Dennis Camporeale Joins Photocure ASA as New CFO to Propel Growth Strategy

Photocure ASA Welcomes Dennis Camporeale as New Chief Financial Officer

In a significant strategic move, Photocure ASA (OSE: PHO), renowned as the Bladder Cancer Company, has announced the appointment of Dennis Camporeale as its Chief Financial Officer (CFO), effective October 26, 2026. Camporeale, an industry veteran with 25 years of expertise, is set to bolster Photocure's financial leadership as the company continues its ambitious growth trajectory.

A Strategic Appointment

Dennis Camporeale's hiring marks a pivotal step for Photocure ASA, which specializes in uro-oncology precision diagnostics. As a seasoned healthcare investment banker and corporate finance leader, Camporeale brings a wealth of experience in dealing with life science tools, diagnostics, and broader healthcare fields. His recent role as head of the Life Science Tools and Diagnostics practice at Canaccord Genuity saw him guiding boards and executive teams on crucial activities including capital raising and mergers and acquisitions (M&A).

Furthermore, Camporeale's operational expertise is highlighted by his impactful tenure at Ally Financial. Here, he played a critical role in transforming GMAC from a captive finance entity into a publicly traded company, overseeing its successful Initial Public Offering (IPO) in the U.S. and managing international divestments. His proficiency in developing financial controls and governance structures will be invaluable as Photocure ASA positions itself for future growth.

CEO Comments

Dan Schneider, the CEO of Photocure, expressed his enthusiasm about the new appointment, stating, "I am delighted to welcome Dennis to Photocure as our new CFO. His extensive experience across medtech, diagnostics, and life sciences investment banking will provide us with critical insight and expertise as we continue to advance our growth strategy. Dennis's leadership is expected to be instrumental in navigating the company's objectives and delivering long-term value to our patients, partners, and shareholders."

Photocure’s Commitment to Innovation

Photocure ASA is dedicated to enhancing health outcomes for patients with urological cancers through innovative diagnostic solutions. With a commitment to precision in uro-oncology, the company aims to utilize cutting-edge technologies to inform personalized patient management. The appointment of Camporeale as CFO aligns with Photocure's vision of implementing transformative solutions that empower healthcare providers to make timely and informed decisions.

The firm, headquartered in Oslo, Norway, is poised for growth as it capitalizes on its unique core technology and emerging portfolio aimed at bettering patient care worldwide. Photocure ASA is listed on the Oslo Stock Exchange under the ticker PHO, and its leadership anticipates that the changes within the executive framework will pave the way for a dynamic phase of development and expansion.

In conclusion, Dennis Camporeale’s appointment not only brings experienced financial acumen to Photocure ASA but also aligns with the company’s drive toward innovation and patient-centric solutions. As he steps into his new role, the healthcare community will be watching closely to see how his leadership will influence the company’s strategic direction and operational effectiveness.

For more information on Photocure ASA and its initiatives, visit www.photocure.com/news.